STOCK TITAN

XTL Biopharma sets vote on up to $1M private placement

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

XTL Biopharmaceuticals Ltd. called an extraordinary meeting for December 28, 2026, with six proposals. Shareholders will vote on Guy Rosen’s election as external director and a proposed grant of options to purchase 1,000,000 ordinary shares, represented by 2,500 ADSs, subject to his election and shareholder approval.

Other proposals cover changing the company’s name to Psyga Ltd., subject to approval by Israel’s Registrar of Companies; Yaron Kopel’s proposed appointment as CEO effective January 1, 2027, subject to shareholder approval, with a NIS 60,000 monthly retainer plus VAT and up to 550,000 options; and reappointing BARZILY & Co. as auditor for 2026. Some proposed CEO terms are not consistent with the company’s compensation policy.

A related-party placement proposal seeks up to US$1,000,000 for up to 769,230 ADSs, representing 307,692,000 ordinary shares, at US$1.30 per ADS. The company says the price is expected to trigger up to 555,556 Series C warrants and a reduction in the exercise price of Series A warrants. Director Alexander Rabinovich, who beneficially held approximately 43.80% of ordinary shares as of November 20, 2026, is among the investors. The placement requires shareholder approval and is not guaranteed; the voting record date is November 30, 2026.

Filing Explained

The December 28, 2026 vote is still required for Kopel’s proposed CEO terms, including options for up to 550,000 ADSs at US$2.30 each; 300,000 milestone options may vest after his engagement ends, and unvested options accelerate on a change of control.

Proposed placement amount Up to US$1,000,000 Private placement, subject to shareholder approval
ADSs in proposed placement Up to 769,230 ADSs Representing 307,692,000 ordinary shares
Placement price US$1.30 per ADS Proposed private placement price
Ordinary shares represented by placement ADSs 307,692,000 ordinary shares Represented by up to 769,230 ADSs
Series C warrants Up to 555,556 warrants Expected to be triggered by the proposed placement price
Proposed Rosen options 1,000,000 ordinary shares (represented by 2,500 ADSs) Subject to his election as external director and shareholder approval
Proposed CEO options Up to 550,000 options Included in Yaron Kopel’s proposed CEO engagement terms
Proposed CEO monthly retainer NIS 60,000 per month Fixed gross management fee, plus value added tax as required by law
external director regulatory
"at least two external directors who meet the statutory requirements of independence"
An external director is a member of a company's board who is not part of its day-to-day management and usually has no material financial ties to the firm. They offer independent oversight and challenge management decisions—like a neutral referee watching for unfair play. For investors, external directors matter because their independence can reduce conflicts of interest, improve governance, and help protect shareholder value by lowering the risk of management missteps.
capital gains track financial
"through a trustee, under the capital gains track"
Milestone Options financial
"the “Milestone Options”"
Minimum Price regulatory
"at a price less than the “Minimum Price”"
The minimum price is the lowest allowable or acceptable price at which a security, share offering, product, or sale can be bought or sold. Think of it like the smallest tag on a store item that the seller will accept; for investors it sets a floor for entry or sale, affects potential returns and liquidity, and can influence demand by limiting purchases below that level.
dormant ordinary shares financial
"excluding 372,957,973 dormant ordinary shares"
Change of Control financial
"Upon a Change of Control (as defined in the Plan)"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is XTLB asking shareholders to approve on December 28, 2026?

XTLB shareholders are being asked to vote on six proposals: Guy Rosen’s election and options, a company name change to Psyga Ltd., Yaron Kopel’s CEO engagement terms, a private placement, and auditor reappointment.

What are the terms of XTLB’s proposed private placement?

The proposed placement is for up to US$1,000,000, with investors purchasing up to 769,230 ADSs at US$1.30 per ADS, representing 307,692,000 ordinary shares. It requires shareholder approval, and the company says it may not be completed.

What compensation is proposed for XTLB’s incoming CEO?

Subject to shareholder approval, Yaron Kopel would become CEO effective January 1, 2027. Proposed terms include a NIS 60,000 monthly retainer plus VAT and up to 550,000 options, each with a US$2.30-per-ADS exercise price.

What options are proposed for XTLB external director nominee Guy Rosen?

The proposed grant is options to purchase 1,000,000 ordinary shares, represented by 2,500 ADSs, subject to Mr. Rosen’s election and shareholder approval. The options would have an exercise price of NIS 0.0148 per ordinary share and vest in 12 equal quarterly installments over 36 months, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of November 2026

 

001-36000

(Commission File Number)

 

XTL Biopharmaceuticals Ltd.

(Exact name of Registrant as specified in its charter)

 

85 Medinat ha-Yehudim St.

Herzliya, 4676670, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒         Form 40-F ☐

 

 

 

 

 

 

On November 20, 2026, XTL Biopharmaceuticals Ltd. (the “Company”) announced that it will hold an Extraordinary General Meeting of Shareholders on Monday, December 28, 2026 at 4:00 p.m. (Israel time) at the offices of the Company’s attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel.  In connection with the meeting, the Company furnishes the following documents:

 

1. A copy of the Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting of Shareholders describing the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the meeting, attached hereto as Exhibit 99.1;

 

2. A form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto as Exhibit 99.2; and

 

Exhibit Index

 

Exhibit No.   Description
     
99.1   Notice and Proxy Statement with respect to the Company’s Extraordinary General Meeting of Shareholders
     
99.2   Proxy Card for holders of ordinary shares with respect to the Company’s Extraordinary General Meeting of Shareholders

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  XTL BIOPHARMACEUTICALS LTD.
   
Date: November 20, 2026 /s/ Noam Band
  Noam Band
  Chief Executive Officer

 

2

 

Exhibit 99.1

 

 

NOTICE OF

EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

TO BE HELD ON DECEMBER 28, 2026

 

To the shareholders of XTL Biopharmaceuticals Ltd.:

 

Notice is hereby given that an Extraordinary General Meeting (the “Meeting”) of the shareholders of XTL Biopharmaceuticals Ltd. (the “Company”) will be held at the offices of the Company’s attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel, on Monday, December 28, 2026 at 4:00 p.m. (Israel time).

 

The agenda of the Meeting will be as follows:

 

1.To elect Mr. Guy Rosen to serve as an external director of the Company, in place of Ms. Iris Shapira Yalon, for an initial term of three (3) years commencing on the date of the Meeting, and to approve his compensation terms;

 

2.Subject to the approval of Proposal 1, to approve the grant of options to purchase 1,000,000 ordinary shares of the Company to Mr. Guy Rosen;

 

3.To approve the change of the Company’s name from “XTL Biopharmaceuticals Ltd.” to “Psyga Ltd.” (in Hebrew: “פסייגה בע"מ”), or such other similar name as shall be approved by the Israeli Registrar of Companies, and to amend the Company’s amended and restated articles of association (the “Articles of Association”) accordingly;

 

4.To approve the engagement terms of Mr. Yaron Kopel as Chief Executive Officer of the Company, including the grant of options to purchase up to 550,000 American Depositary Shares of the Company (“ADSs”), each ADS representing 400 ordinary shares of the Company;

 

5.To approve, including for the purpose of Nasdaq Rules 5635(c) and 5635(d), a private placement of up to US$1,000,000 from certain investors, including Mr. Alexander Rabinovich, a director of the Company (the “Interested Party”), and the issuance of all ordinary shares (including in the form of ADSs) issuable in connection therewith or as a result thereof, including upon exercise of any warrants issued or repriced as a result of the private placement, as described in the Proxy Statement; and

 

6.To approve the re-appointment of Barzily & Co. C.P.A. as the Company’s independent registered public accounting firm for the year ending December 31, 2026, and to authorize the Board of Directors, upon the recommendation of the Audit Committee, to determine the auditors’ remuneration in accordance with the volume and nature of their services.

 

Only shareholders and holders of ordinary shares represented by American Depositary Shares at the close of business on November 30, 2026 are entitled to notice of, and to vote at, the Meeting and any adjournment or postponement thereof. You are cordially invited to attend the Meeting in person.

 

If you are unable to attend the Meeting in person, you are requested to complete, date and sign the enclosed proxy and to return it promptly in the pre-addressed envelope provided. Shareholders who attend the Meeting may revoke their proxies and vote their shares in person.

 

Beneficial owners who hold ordinary shares through members of the Tel Aviv Stock Exchange, or the TASE, may either vote their shares in person at the Meeting by presenting a certificate signed by the TASE Clearing House member through which the shares are held, which complies with the Israel Companies Regulations (Proof of Ownership for Voting in General Meetings)-2000 as proof of ownership of the shares on the record date, or send such certificate along with a duly executed proxy (in the form filed by us on MAGNA, the distribution site of the Israeli Securities Authority, at www.magna.isa.gov.il), to us at 85 Medinat ha-Yehudim St. Herzliya, 4676670, Israel, Attention: Chief Executive Officer.

 

  By Order of the Board of Directors
   
  /s/ Noam Band
  Noam Band
  Chief Executive Officer
  November 20, 2026

 

 

 

 

 

85 Medinat ha-Yehudim St.

Herzliya, 4676670, Israel

PROXY STATEMENT

 

FOR AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

TO BE HELD ON DECEMBER 28, 2026

 

This Proxy Statement is furnished to our holders of ordinary shares, par value NIS 0.1 per share and holders of our ordinary shares that are represented by American Depository Shares, or ADSs, in connection with an Extraordinary General Meeting of Shareholders, to be held on Monday, December 28, 2026, at 4:00 p.m. Israel time at the offices of the Company’s attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel, or at any adjournments thereof.

 

Throughout this Proxy Statement, we use terms such as “XTL Biopharmaceuticals,” “XTL,” “we”, “us”, “our” and the “Company” to refer XTL Biopharmaceuticals Ltd. and terms such as “you” and “your” to refer to our shareholders and ADS holders.

 

Agenda Items

 

The agenda of the extraordinary meeting will be as follows:

 

1.To elect Mr. Guy Rosen to serve as an external director of the Company, in place of Ms. Iris Shapira Yalon, for an initial term of three (3) years commencing on the date of the Meeting, and to approve his compensation terms;

 

2.Subject to the approval of Proposal 1, to approve the grant of options to purchase 1,000,000 ordinary shares of the Company to Mr. Guy Rosen;

 

3.To approve the change of the Company’s name from “XTL Biopharmaceuticals Ltd.” to “Psyga Ltd.” (in Hebrew: “פסייגה בע”מ”), or such other similar name as shall be approved by the Israeli Registrar of Companies, and to amend the Company’s amended and restated articles of association (the “Articles of Association”) accordingly;

 

4.To approve the engagement terms of Mr. Yaron Kopel as Chief Executive Officer of the Company, including the grant of options to purchase up to 550,000 ADSs of the Company;

 

5.To approve, including for the purpose of Nasdaq Rules 5635(c) and 5635(d), a private placement of up to US$1,000,000 from certain investors, including Mr. Alexander Rabinovich, a director of the Company (the “Interested Party”), and the issuance of all ordinary shares (including in the form of ADSs) issuable in connection therewith or as a result thereof, including upon exercise of any warrants issued or repriced as a result of the private placement, as described in the Proxy Statement; and

 

6.To approve the re-appointment of Barzily & Co. C.P.A. as the Company’s independent registered public accounting firm for the year ending December 31, 2026, and to authorize the Board of Directors, upon the recommendation of the Audit Committee, to determine the auditors’ remuneration in accordance with the volume and nature of their services.

 

We are currently unaware of any other matters that may be raised at the Meeting. Should any other matters be properly raised at the Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.

 

Page 2

 

 

Board Recommendation

 

Our Board of Directors unanimously recommends that you vote “FOR” all items.

 

Who Can Vote

 

Only shareholders and ADS holders at the close of business on November 30, 2026 shall be entitled to receive notice of and to vote at the extraordinary meeting.

 

How You Can Vote

 

You can vote your ordinary shares by attending the extraordinary meeting. If you do not plan to attend the extraordinary meeting, the method of voting will differ for shares held as a record holder, shares held in “street name” (through a Tel Aviv Stock Exchange, or TASE, member) and shares underlying ADSs that you hold. Record holders of shares will receive proxy cards. Holders of shares in “street name” through a TASE member will also vote via a proxy card, but through a different procedure (as described below). Holders of ADSs (whether registered in their name or in “street name”) will receive voting instruction cards in order to instruct their banks, brokers or other nominees on how to vote.

 

Shareholders of Record

 

If you are a shareholder of record, you can submit your vote by completing, signing and submitting a proxy card, which has been published at www.magna.isa.gov.il, to the Company’s office at 85 Medinat ha-Yehudim St., Herzliya 4676670, Israel.

 

Please follow the instructions on the proxy card.

 

Shareholders Holding in “Street Name” through the TASE

 

If you hold ordinary shares in “street name,” that is, through a bank, broker or other nominee that is admitted as a member of the TASE, your shares will only be voted if you provide instructions to the bank, broker or other nominee as to how to vote, or if you attend the extraordinary meeting in person.

 

If voting by mail, you must sign and date a proxy card in the form filed by us on MAGNA on November 20, 2026 and attach to it a certificate signed by the TASE Clearing House member through which the shares are held, which complies with the Israel Companies Regulations (Proof of Ownership for Voting in General Meetings)-2000 as proof of ownership of the shares on the record date, and return the proxy card, along with the proof of ownership certificate, to the offices of our attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel, as described in the instructions available on MAGNA.

 

If you choose to attend the extraordinary meeting (where ballots will be provided), you must bring the proof of ownership certificate from the TASE’s Clearing House member through which the shares are held, indicating that you were the beneficial owner of the shares on the record date.

 

Page 3

 

 

Holders of ADSs

 

Under the terms of the Deposit Agreement between the Company, The Bank of New York Mellon, as depositary, or BNY Mellon, and the holders of our ADSs, BNY Mellon shall endeavor (insofar as is practicable) to vote or cause to be voted the number of shares represented by ADSs in accordance with the instructions provided by the holders of ADSs to BNY Mellon. For ADSs that are held in “street name”, through a bank, broker or other nominee, the voting process will be based on the underlying beneficial holder of the ADSs directing the bank, broker or other nominee to arrange for BNY Mellon to vote the ordinary shares represented by the ADSs in accordance with the beneficial holder’s voting instructions. If no instructions are received by BNY Mellon from any holder of ADSs (whether held directly by a beneficial holder or in “street name”) with respect to any of the shares represented by the ADSs on or before the date established by BNY Mellon for such purpose, BNY Mellon shall not vote or attempt to vote the shares represented by such ADSs.

 

Multiple Record Shareholders or Accounts

 

You may receive more than one set of voting materials, including multiple copies of this document and multiple proxy cards or voting instruction cards. For example, shareholders who hold ADSs in more than one brokerage account will receive a separate voting instruction card for each brokerage account in which ADSs are held. Shareholders of record whose shares are registered in more than one name will receive more than one proxy card. You should complete, sign, date and return each proxy card and voting instruction card you receive.

 

Our Board of Directors urges you to vote your shares so that they will be counted at the extraordinary meeting or at any postponements or adjournments of the extraordinary meeting.

 

Solicitation of Proxies

 

By appointing “proxies”, shareholders and ADS holders may vote at the extraordinary meeting whether or not they attend. If a properly executed proxy in the attached form is received by us at least 48 hours prior to the extraordinary meeting (and received by BNY Mellon no later than the date indicated on the voting instruction card, in the case of ADS holders), all of the shares represented by the proxy shall be voted as indicated on the form or, if no preference is noted, shall be voted in favor of the matter described above, and in such manner as the holder of the proxy may determine with respect to any other business as may come before the extraordinary meeting or any adjournment thereof.  Shareholders and ADS holders may revoke their proxies at any time before the deadline for receipt of proxies by filing with us (in the case of holders of ordinary shares) or with BNY Mellon (in the case of holders of ADSs), a written notice of revocation or duly executed proxy bearing a later date.

 

Proxies are being distributed to shareholders and ADS holders on or about November 30, 2026. Certain officers, directors, employees, and agents of ours, none of whom will receive additional compensation therefor, may solicit proxies by telephone, emails, or other personal contact. We will bear the cost for the solicitation of the proxies, including postage, printing, and handling, and will reimburse the reasonable expenses of brokerage firms and others for forwarding material to beneficial owners of shares and ADSs.

 

To the extent you would like to submit a position statement with respect to any of the proposals described in this proxy statement pursuant to the Israeli Companies Law 5759-1999 (the “Companies Law”), you may do so by delivery of appropriate notice to the offices of our attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel, not later than ten days before the convening of the extraordinary meeting (i.e., Friday, December 18, 2026). Response of the Board to the position statement may be submitted not later than five days after the deadline for sending the position statement (i.e., Wednesday, December 23, 2026).

 

Page 4

 

 

Quorum

 

At the close of business on November 19, 2026, we had outstanding 1,741,835,356 ordinary shares, and excluding 372,957,973 dormant ordinary shares. Each ordinary share (including ordinary shares represented by ADSs) outstanding as of the close of business on the record date is entitled to one vote upon each of the matters to be voted on at the extraordinary meeting.

 

The quorum required to hold the Meeting consists of at least two shareholders present in person or by proxy who hold or represent between them at least one-third of the voting rights in the Company. If the Meeting is adjourned for lack of a quorum it will be held on the same day in the following week at the same time and place (with no need for any notice to the shareholders) or until such other later time if we serve notice to the shareholders no less than seven days before the date fixed for the such adjourned meeting (the “Deferred Meeting”). If at a Deferred Meeting there is no quorum present half an hour after the time set for the meeting, any number participating in the Deferred Meeting shall represent a quorum and shall be entitled to discuss the matters set down on the agenda for the original Meeting.

 

Vote Required for Each Proposal

 

The affirmative vote of the holders of a majority of the voting power represented and voting on such Proposals in person or by proxy at the extraordinary meeting is necessary for the approval of each of Proposals 1 through 6.

 

In addition, the approval of each of Proposals 1, 2, 4 and 5 must either include at least a majority of the ordinary shares voted by shareholders who are not controlling shareholders nor are they shareholders who have a personal interest in the proposal, or the total ordinary shares of non-controlling shareholders and non-interested shareholders voted against the proposal must not represent more than 2% of the outstanding ordinary shares.

 

Under the Companies Law, in general, you will be deemed to be a controlling shareholder if you have the power to direct our activities, otherwise than by reason of being a director or other office holder of ours, if you hold 25.0% or more of the voting rights in our Company or have the right to appoint the majority of the directors of the Company or its chief executive officer, and you are deemed to have a personal interest if any member of your immediate family or their spouse has a personal interest in the adoption of the proposal. In addition, you are deemed to have a personal interest if a company, other than XTL Biopharmaceuticals, that is affiliated to you has a personal interest in the adoption of the proposal. Such company is a company in which you or a member of your immediate family serves as a director or chief executive officer, has the right to appoint a director or the chief executive officer, or owns 5% or more of the outstanding shares. However, you are not deemed to have a personal interest in the adoption of the proposal if your interest in such proposal arises solely from your ownership of our shares, or to a matter that is not related to a relationship with a controlling shareholder.

 

According to the Companies Regulations (exemptions for companies whose securities are listed for trading on a stock exchange outside of Israel) 5760-2000 (the “Exemption Regulations for Companies Listed Abroad”), by signing and submitting the attached Proxy Card, you as a shareholder declare and approve that you have no personal interest in the adoption of Proposals 1, 2, 4 and 5, except if you notified the Company of such in writing. If you believe that you have a personal interest in Proposal 1, Proposal 2, Proposal 4 or Proposal 5, and you wish to inform the Company of such personal interest, you should submit such information in advance of voting to the Company at its registered offices at XTL Biopharmaceuticals Ltd., 85 Medinat ha-Yehudim St., Herzliya 4676670, Israel, to the attention of the Chief Financial Officer.

 

Page 5

 

 

If you provide specific instructions (mark boxes) with regard to certain Proposals, your shares will be voted as you instruct. If you sign and return your proxy card or voting instruction form without giving specific instructions, your shares will be voted in accordance with the recommendations of our Board of Directors. The proxy holders will vote in their discretion on any other matters that properly come before the extraordinary meeting.

 

If you are a shareholder of record and do not return your proxy card, your shares will not be voted. If you hold shares (or ADSs representing shares) beneficially in street name, your shares will also not be voted at the extraordinary meeting if you do not return your proxy card or voting instruction card to instruct your broker or BNY Mellon how to vote. For all proposals, a broker (and BNY Mellon) may only vote in accordance with instructions from a beneficial owner of shares or ADSs, as your broker and BNY Mellon will not be permitted to vote your shares in their discretion on any proposal at the extraordinary meeting.

 

Availability of Proxy Materials

 

Copies of the proxy card and voting instruction card, the Notice of the Extraordinary Meeting and this Proxy Statement are available at the “Investor Information” portion of our website, http://www.xtlbio.com/. The contents of that website are not a part of this Proxy Statement.

 

Reporting Requirements

 

We are subject to the information reporting requirements of the Securities Exchange Act of 1934, as amended, or Exchange Act, applicable to foreign private issuers. We fulfill these requirements by filing reports with the Securities and Exchange Commission, or Commission. Our filings are available to the public on the Commission’s website at http://www.sec.gov.

 

As a foreign private issuer, we are exempt from the rules under the Securities Exchange Act, or Exchange Act of 1934, as amended, related to the furnishing and content of proxy statements. The circulation of this notice and proxy statement should not be taken as an admission that we are subject to the proxy rules under the Exchange Act.

 

PROPOSAL 1:

ELECTION OF AN EXTERNAL DIRECTOR

 

Background

 

In accordance with the Companies Law and the relevant regulations, we must have at least two external directors who meet the statutory requirements of independence. Under the Companies Law, an external director serves for a term of three years, which may be extended for additional three-year terms. Further, an external director can be removed from office only under very limited circumstances. In addition, under the Companies Law, all of the external directors must serve on our audit committee and compensation committee (including one external director serving as the chair of our audit committee and as the chair of our compensation committee), and at least one external director must serve on each other committee of our Board of Directors.

 

To qualify as an external director, an individual must meet various independence requirements, including that such individual may not have, and may not have had at any time during the previous two years, any “affiliation” (as defined in the Companies Law) with the Company or with certain of its affiliates. In addition, no individual may serve as an external director if the individual’s position or other activities create or may create a conflict of interest with his or her role as an external director. Mr. Guy Rosen has submitted a declaration to the Company confirming that he satisfies the qualifications of an external director under the Companies Law and that he possesses accounting and financial expertise and professional qualifications, and the Board has so determined.

 

Page 6

 

 

Mr. Guy Rosen’s candidacy is to serve in lieu of Ms. Iris Shapira Yalon, who, on October 12, 2026, notified the Company of her resignation as an external director, effective as of the earlier of November 20, 2026 and the appointment of a new external director, for personal reasons and not due to any disagreement with the Company or any matter relating to its operations. Ms. Shapira Yalon’s resignation became effective on November 20, 2026. Mr. Rosen was nominated in lieu of Mr. Gilai Dolev, whose nomination was reported on the Company’s Form 6-K furnished on October 14, 2026, and who withdrew his candidacy for personal reasons and not due to any disagreement with the Company. If elected as an external director, Mr. Rosen will serve as a member of our audit committee and compensation committee.

 

Biographical information concerning Mr. Rosen is set forth below.

 

Guy Rosen. Mr. Guy Rosen currently serves as Chairman of the Board of Directors of Millennium Food-Tech Ltd. (TASE) and of BloomX Ltd., and as a member of the boards of directors of Mizrahi Invest, Albaad Ltd. (TASE), Altitude Ltd. (TASE), Robogroup Ltd. (TASE) and S. Baruch Ltd. (TASE). Mr. Rosen previously served as Vice Chairman of Tnuva, Israel’s largest food group, as Deputy Chief Executive Officer of Clal Industries Ltd. and as Executive Director of the Infinity I-China Fund. Mr. Rosen has also previously served as Chairman of the Board of Directors of Bet Shemesh Engines Ltd. (TASE), Kitan Industries Ltd., Israir Ltd. and Aviv Shigur Ltd., and as a member of the boards of directors of Isramco Negev 2 LP (TASE), IDB Tourism, Taavura, Netvision, Barak 013, Shellcase, Cargal and Plasto-Sac. Mr. Rosen holds an LL.B. (cum laude) from Tel Aviv University and an M.B.A. (cum laude) from the Interdisciplinary Center (IDC) Herzliya, and completed the Advanced Management Program (AMP) at Harvard Business School. Mr. Rosen served in the Israeli Air Force and holds the rank of Lieutenant Colonel (Res.).

 

Subject to his election, and in accordance with the Companies Regulations (Rules Regarding Compensation and Expenses of an External Director), 5760-2000 (the “Compensation Regulations”) and the Company’s Compensation Policy, Mr. Rosen will be entitled to the following compensation for his service as an external director, based on the Company’s classification as a Rank A company under the First Addendum to the Compensation Regulations (shareholders’ equity of up to approximately NIS 50.3 million): (A) Annual Fee: pursuant to Regulation 4 of the Compensation Regulations, an annual fee equal to the “fixed amount” set forth in the Second Addendum to the Compensation Regulations for a Rank A company, which, as of the date of this Proxy Statement, is NIS 33,565 (approximately US$10,227), payable in four (4) equal quarterly installments at the beginning of each quarter in respect of the preceding quarter, and pro rata for any partial year of service; (B) Participation Fee: pursuant to Regulation 5 of the Compensation Regulations, a participation fee for each meeting of the Board of Directors or of a committee thereof (including the Audit Committee) in which he participates, equal to the “fixed amount” set forth in the Third Addendum to the Compensation Regulations for a Rank A company, which, as of the date of this Proxy Statement, is NIS 1,065 (approximately US$325) per meeting; for participation in a meeting by means of telecommunication, the participation fee will be 60% of such amount (NIS 639), and for a resolution adopted without an actual convening, 50% of such amount (NIS 532.50); (C) Expenses: reimbursement of expenses in accordance with Regulation 6 of the Compensation Regulations; and (D) Equity Compensation: subject to the approval of Proposal 2, the External Director Options (as defined in Proposal 2 below). The annual fee and participation fee amounts are linked to the Israeli consumer price index and will be updated, and adjusted for any change in the Company’s rank, in accordance with the Compensation Regulations. In addition, Mr. Rosen will be entitled to the Company’s standard exculpation and indemnification undertaking and to coverage under the Company’s directors’ and officers’ liability insurance policy, on the same terms as the Company’s other directors.

 

Proposed Resolution

 

It is therefore proposed that the following resolution be adopted at the Meeting:

 

“RESOLVED, that the election of Mr. Guy Rosen as an external director of the Company, to serve for a three-year term commencing on the date of the Meeting and ending December 27, 2029, be, and hereby is, approved in all respects.”

 

Page 7

 

 

Required Vote

 

Under the Companies Law, the affirmative vote of the holders of a majority of the ordinary shares represented at the Meeting, in person or by proxy, entitled to vote and voting on the matter, is required for this proposal. In addition, the shareholders’ approval must either include at least a majority of the ordinary shares voted by shareholders who are neither controlling shareholders nor shareholders who have a personal interest in the approval of this proposal, or the total ordinary shares of such non-controlling and non-interested shareholders voted against this proposal must not represent more than 2% of the outstanding ordinary shares.

 

Please note that, according to the Exemption Regulations for Companies Listed Abroad, by signing and submitting the attached proxy card you, as a shareholder, declare and approve that you are neither a controlling shareholder nor have a personal interest in the adoption of this proposal, except if you have notified the Company of such in writing. If you believe that you have a personal interest in this proposal and you wish to inform the Company of such personal interest, you should submit such information in advance of voting to the Company at its registered offices at XTL Biopharmaceuticals Ltd., 85 Medinat ha-Yehudim St., Herzliya, Israel, to the attention of Mr. Noam Band, Chief Executive Officer.

 

Board Recommendation

 

Our Board of Directors recommends a vote FOR the foregoing proposal.

 

PROPOSAL 2:

APPROVAL OF THE GRANT OF OPTIONS TO MR. GUY ROSEN, NOMINEE FOR EXTERNAL DIRECTOR

 

Background

 

Under the Companies Law, the compensation of directors, including equity-based compensation, requires the approval of the Compensation Committee, the Board of Directors and the shareholders, in that order. The compensation of an external director is subject to the Compensation Regulations, which permit the grant of equity-based compensation to an external director subject to the conditions set forth therein. The Compensation Committee and the Board of Directors have determined that the proposed grant to Mr. Rosen complies with the Compensation Regulations and is consistent with the Company's Compensation Policy.

 

On November 17, 2026, our Compensation Committee and Board of Directors approved, subject to the approval of Proposal 1 and to shareholder approval, the grant to Mr. Guy Rosen of options to purchase 1,000,000 ordinary shares of the Company, represented by 2,500 ADSs, under the Company’s 2026 Global Share Incentive Plan (the “Plan”) (the “External Director Options”). The External Director Options will have an exercise price of NIS 0.0148 (1.48 agorot) per ordinary share, will vest in twelve (12) equal quarterly installments over a period of thirty-six (36) months commencing on the date of the Meeting, subject to Mr. Rosen’s continued service as a director of the Company, and will expire ten (10) years following the date of grant. The External Director Options will be granted under Section 102 of the Israeli Income Tax Ordinance [New Version], 5721-1961 (the “ITO”), through a trustee, under the capital gains track. All other terms of the External Director Options will be in accordance with the Plan.

 

The Compensation Committee and the Board of Directors determined that the grant of the External Director Options is consistent with the Company’s Compensation Policy and the Compensation Regulations and is in the best interests of the Company.

 

Page 8

 

 

Proposed Resolution

 

It is proposed that at the Meeting the following resolution be adopted:

 

“RESOLVED, subject to the approval of Proposal 1, to approve the grant to Mr. Guy Rosen of options to purchase 1,000,000 ordinary shares of the Company, represented by 2,500 ADSs, upon the terms described above.”

 

Required Vote

 

Under the Companies Law, the affirmative vote of the holders of a majority of the ordinary shares represented at the Meeting, in person or by proxy, entitled to vote and voting on the matter, is required for this proposal. In addition, the shareholders’ approval must either include at least a majority of the ordinary shares voted by shareholders who are neither controlling shareholders nor shareholders who have a personal interest in the approval of this proposal, or the total ordinary shares of such non-controlling and non-interested shareholders voted against this proposal must not represent more than 2% of the outstanding ordinary shares.

 

Please note that, according to the Exemption Regulations for Companies Listed Abroad, by signing and submitting the attached proxy card you, as a shareholder, declare and approve that you are neither a controlling shareholder nor have a personal interest in the adoption of this proposal, except if you have notified the Company of such in writing. If you believe that you have a personal interest in this proposal and you wish to inform the Company of such personal interest, you should submit such information in advance of voting to the Company at its registered offices at XTL Biopharmaceuticals Ltd., 85 Medinat ha-Yehudim St., Herzliya, Israel, to the attention of Mr. Noam Band, Chief Executive Officer.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” approval of the proposed resolution.

 

PROPOSAL 3:

CHANGE OF THE COMPANY’S NAME

FROM XTL BIOPHARMACEUTICALS LTD. TO PSYGA LTD.

 

Background

 

On November 12, 2026, our Board of Directors approved, subject to shareholder approval, the change of the Company’s name from XTL Biopharmaceuticals Ltd. to Psyga Ltd. (in Hebrew: “פסייגה בע"מ”) (the “Change of Name”). On June 30, 2026, the Company completed the acquisition of a controlling interest in Psyga Bio Ltd., an Israeli biotechnology company focused on psychedelic and functional mushroom-derived products, as described in the Company’s Report on Form 6-K furnished to the SEC on that date. Following that acquisition, psychedelic medicine has become the Company’s core business. The Board believes that the new name will more accurately reflect the Company’s current scope of operations, better align its corporate identity with its strategy and vision, and reinforce its competitive positioning within the industries in which it conducts business. The Board further believes that the Change of Name will enhance the clarity of the Company's mission for stakeholders, partners, and customers, and is expected to support the Company's initiatives to pursue new business opportunities, strengthen investors’ confidence, and facilitate entry into new markets.

 

Proposed Resolution

 

It is proposed that at the Meeting the following resolution be adopted:

 

“RESOLVED, to approve, subject to and conditional upon the approval of the Registrar of Companies of Israel, the change of the name of the Company from XTL Biopharmaceuticals Ltd. to Psyga Ltd., and to amend the Company’s Articles of Association accordingly”

 

Required Vote

 

The affirmative vote of the holders of a majority of the voting power represented and voting on this proposal in person or by proxy is necessary for the approval of the resolution to approve the Change of Name and the corresponding amendment to the Company’s Articles.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” approval of the proposed resolution.

 

Page 9

 

 

PROPOSAL 4

APPROVAL OF THE ENGAGEMENT TERMS OF MR. YARON KOPEL AS CHIEF

EXECUTIVE OFFICER

 

Background

 

On November 17, 2026, our Board of Directors approved, subject to the approval of the shareholders of the Company at the Meeting, the appointment of Mr. Yaron Kopel as the Chief Executive Officer of the Company (the “CEO”), in place of Mr. Noam Band, effective as of January 1, 2027, the date on which Mr. Band’s resignation as Chief Executive Officer will become effective (the “Effective Date”). Mr. Band will continue to serve as the Company’s Chief Executive Officer until the Effective Date.

 

During the interim period commencing on December 1, 2026 and ending on the Effective Date, Mr. Kopel will provide consulting services to the Company and will not serve as an office holder of the Company during such period.

 

On November 17, 2026, following the approval of our Compensation Committee on the same date, our Board of Directors approved, subject to the approval of the shareholders of the Company, the terms of office and engagement of Mr. Kopel as CEO, pursuant to a service agreement to be entered into between the Company and Mr. Kopel, or a company wholly owned and controlled by him (the “Service Agreement”). Mr. Kopel shall provide his services to the Company as an independent contractor and shall report to the Board of Directors. The principal terms of the Service Agreement are as follows: (A) Monthly Retainer Fee: a fixed gross monthly management fee of NIS 60,000 (sixty thousand New Israeli Shekels), plus value added tax as required by law, payable against a duly issued tax invoice (the “Retainer Fee”). Mr. Kopel shall not be entitled to any social benefits or other payments customarily paid to employees; (B) Options: Mr. Kopel shall be granted, without consideration, up to 550,000 (five hundred and fifty thousand) non-tradable options, each exercisable into one (1) ADS of the Company (or the equivalent number of ordinary shares) (the “CEO Options”), under the Plan, to vest as follows: (i) 150,000 CEO Options shall be fully vested on the Effective Date; (ii) 300,000 CEO Options shall vest in three (3) equal tranches of 100,000 CEO Options each, conditioned upon the occurrence of each of the three (3) milestones set forth in the share purchase agreement between the Company and the shareholders of Psyga Bio Ltd. (“Psyga”), concurrently with the issuance of the corresponding milestone securities to such shareholders, whether or not Mr. Kopel is then engaged by the Company (the “Milestone Options”); and (iii) 100,000 CEO Options shall vest in twelve (12) equal quarterly installments over a period of three (3) years commencing on the Effective Date, subject to the continued engagement of Mr. Kopel with the Company on each vesting date. The CEO Options shall be granted to Mr. Kopel personally, pursuant to the capital gains track of Section 102 of the ITO, through a trustee (or, if Section 102 does not apply, pursuant to Section 3(i) thereof), as soon as practicable following the approval of the shareholders and the adoption of the Plan and its filing with the Israel Tax Authority.(C) Exercise Price, Term, Termination and Change of Control: the exercise price of each CEO Option shall be US$2.30 per ADS, and the CEO Options shall expire five (5) years following the date of grant. Upon termination of the Service Agreement for any reason (including for cause), (a) the CEO Options described in paragraph (iii) above shall cease to vest; (b) the Milestone Options shall continue to vest upon the occurrence of the relevant milestone; and (c) vested CEO Options shall remain exercisable for a period of twelve (12) months following termination (or, with respect to Milestone Options vesting after termination, following the date of vesting), but in no event after the expiration of their term. Upon a Change of Control (as defined in the Plan), all unvested CEO Options, including the Milestone Options (whether or not the relevant milestone has then occurred), shall accelerate and become fully vested and exercisable immediately prior to, and conditioned upon, the consummation of the Change of Control; and (D) Other Terms: the Service Agreement is for an indefinite term and may be terminated by either party upon sixty (60) days’ prior written notice, by the Company immediately for cause, and by Mr. Kopel for good reason, each as defined in the Service Agreement. Mr. Kopel may be eligible for an annual or one-time bonus, if and to the extent approved by the Company’s competent organs in accordance with the Company’s Compensation Policy and applicable law. The Service Agreement further includes provisions regarding reimbursement of expenses, confidentiality, assignment of intellectual property, non-competition and non-solicitation, the absence of employer-employee relationship, exemption, indemnification and directors’ and officers’ liability insurance (on the terms applicable to the Company’s other office holders), and other terms, all as customary in agreements of this kind and as applicable (collectively with the foregoing, the “CEO Engagement Terms”).

 

Page 10

 

 

Under Section 272(c1) of the Companies Law, terms of office and employment of a chief executive officer that are not in accordance with the company’s compensation policy require the approval of the compensation committee, the board of directors and the shareholders, by the special majority described below, in that order. Certain of the CEO Engagement Terms are not in accordance with the Company’s Compensation Policy, namely (i) the vesting of 150,000 CEO Options on the Effective Date and the milestone-based vesting of the Milestone Options, rather than over the minimum vesting period prescribed by the Compensation Policy; (ii) the continued vesting of the Milestone Options following termination, including for cause; (iii) the twelve (12) month post-termination exercise period; (iv) the full acceleration of all unvested CEO Options upon a Change of Control; and (v) the value of the CEO Options, which exceeds the cap on equity-based compensation set forth in the Compensation Policy.

 

In approving the CEO Engagement Terms, including such terms, the Compensation Committee and the Board of Directors considered, among other things, the considerations and matters set forth in Section 267B(a) and Parts A and B of the First Addendum to the Companies Law, Mr. Kopel’s education, qualifications, expertise and professional experience, and the alignment of a substantial portion of his compensation with the achievement of the Psyga milestones and with long-term shareholder value, and determined that the CEO Engagement Terms are fair, reasonable and in the best interests of the Company.

 

Yaron Kopel. Since 2019, Mr. Kopel has served as a private investor, through K.Y. Liam Ltd., and as a director of private and public companies in the consumer, technology and health-tech sectors. Mr. Kopel was the first investor in UserWay and served as its Chief Business Officer until its acquisition by KKR. From 2017 to 2021, Mr. Kopel served as Founder and Chief Executive Officer of Meet-In-Place, a global provider of off-site meeting spaces. From 2010 to 2017, Mr. Kopel served as Chief Products, Marketing, Innovation & Design Officer of SodaStream International Ltd. (then Nasdaq: SODA). From 2008 to 2010, Mr. Kopel served as Chief Marketing & Innovation Officer of Excellence Nessuah, an Israeli investment house, and from 2000 to 2008 he founded and led several retail and e-commerce ventures, including Te Casan, ZER4U and Shenkin Candles. From 1997 to 2000, Mr. Kopel served as Retail & Products Manager at Microsoft Israel. Mr. Kopel was named Israel’s Entrepreneur of the Year in 2003. Mr. Kopel holds a B.B.A. from Tel Aviv College.

 

Proposed Resolution

 

It is proposed that at the Meeting the following resolution be adopted:

 

“RESOLVED, to approve the engagement terms of Mr. Yaron Kopel as Chief Executive Officer of the Company, including the grant of the CEO Options, as described in this Proxy Statement, effective as of the Effective Date, notwithstanding that certain of such terms are not consistent with the Company’s Compensation Policy.”

 

Required Vote

 

Under the Companies Law, the affirmative vote of the holders of a majority of the ordinary shares represented at the Meeting, in person or by proxy, entitled to vote and voting on the matter, is required for this proposal. In addition, the shareholders’ approval must either include at least a majority of the ordinary shares voted by shareholders who are neither controlling shareholders nor shareholders who have a personal interest in the approval of this proposal, or the total ordinary shares of such non-controlling and non-interested shareholders voted against this proposal must not represent more than 2% of the outstanding ordinary shares.

 

Please note that, according to the Exemption Regulations for Companies Listed Abroad, by signing and submitting the attached proxy card you, as a shareholder, declare and approve that you are neither a controlling shareholder nor have a personal interest in the adoption of this proposal, except if you have notified the Company of such in writing. If you believe that you have a personal interest in this proposal and you wish to inform the Company of such personal interest, you should submit such information in advance of voting to the Company at its registered offices at XTL Biopharmaceuticals Ltd., 85 Medinat ha-Yehudim St., Herzliya, Israel, to the attention of Mr. Noam Band, Chief Executive Officer.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” approval of the proposed resolution.

 

Page 11

 

 

PROPOSAL 5

PRIVATE PLACEMENT – INTERESTED PARTY TRANSACTION

 

Background

 

On November 17, 2026, our Audit Committee and Board of Directors approved, subject to shareholder approval, a private placement in the aggregate amount of up to US$1,000,000 (the “Private Placement”) to certain investors, including Mr. Alexander Rabinovich, a director of the Company, who as of November 20, 2026 beneficially holds in the aggregate approximately 43.80% of the Company’s ordinary shares and is the Chairman and a shareholder of Psyga (the “Interested Party”). Under the Private Placement, the investors will purchase up to 769,230 ADSs, representing 307,692,000 Ordinary Shares, at a purchase price of US$1.30 per ADS with the number of ADS rounded down to the nearest whole number such that no fractional ADSs or Ordinary Shares will be issued. There will not be a placement agent in connection with the Private Placement.

 

Because the Company’s ADSs are listed on the Nasdaq Stock Market, the Company is subject to Nasdaq Rule 5635(c), which requires shareholder approval of equity compensation, which, under Nasdaq’s interpretation, includes any issuance of securities (other than in a public offering) to an officer, director, employee or consultant at a price less than the “market value” of the stock. The purchase price of US$1.30 per ADS may be less than such market value at the time the Company enters into the definitive purchase agreement with the Interested Party. Accordingly, the Company is seeking shareholder approval of the Private Placement, including the issuance of ADSs to the Interested Party, for purposes of Nasdaq Rule 5635(c). If such approval is not obtained, the Company will not issue ADSs to the Interested Party at a price below market value. The Company is also subject to Nasdaq Rule 5635(d), which requires shareholder approval prior to a transaction, other than a public offering, involving the sale, issuance or potential issuance of ordinary shares (or securities convertible into or exercisable for ordinary shares) which alone or together with sales by officers, directors or substantial shareholders equals 20% or more of the ordinary shares or voting power outstanding before the issuance, at a price less than the “Minimum Price”. The purchase price of US$1.30 per ADS is expected to be less than the Minimum Price. In addition, because the purchase price is below US$2.70 per ADS, the Private Placement is expected to trigger (i) the issuance of up to 555,556 Series C warrants (and the corresponding warrants issued in the additional June 2026 round) to the investors in the Company’s June 2026 private placement and (ii) a reduction of the exercise price of the Series A warrants issued in that private placement. The Ordinary Shares issuable in the Private Placement, together with the Ordinary Shares underlying such Series C warrants, and, to the extent aggregated by Nasdaq, the securities issued in the Company’s June 2026 private placement, may equal or exceed 20% of the Company’s outstanding ordinary shares prior to the issuance. Accordingly, the Company is also seeking shareholder approval of the Private Placement, and of the issuance of all ordinary shares issuable as a result thereof, for purposes of Nasdaq Rule 5635(d). Because the Interested Party already holds the largest ownership position in the Company, the Company does not believe that the Private Placement will result in a change of control for purposes of Nasdaq Rule 5635(b).In addition, the participation of the Interested Party requires approval under the Companies Law. There is no guarantee that the Private Placement will be consummated as described or at all.

 

Proposed Resolution

 

It is proposed that at the Meeting the following resolution be adopted:

 

“RESOLVED, to approve, including for the purpose of Nasdaq Rules 5635(c) and 5635(d), the Private Placement of up to US$1,000,000 from certain investors, including the Interested Party, and the issuance of all ordinary shares (including in the form of ADSs) issuable in connection therewith or as a result thereof, including upon exercise of any warrants issued or repriced as a result of the Private Placement, as described in this Proxy Statement.”

 

Page 12

 

 

Required Vote

 

The affirmative vote of the holders of a majority of the voting power represented and voting on this proposal in person or by proxy is required for this proposal. In addition, the shareholders’ approval must either include at least a majority of the ordinary shares voted by shareholders who are neither controlling shareholders nor shareholders who have a personal interest in the approval of this proposal, or the total ordinary shares of such non-controlling and non-interested shareholders voted against this proposal must not represent more than 2% of the outstanding ordinary shares.

 

Please note that, according to the Exemption Regulations for Companies Listed Abroad, by signing and submitting the attached proxy card you, as a shareholder, declare and approve that you are neither a controlling shareholder nor have a personal interest in the adoption of this proposal, except if you have notified the Company of such in writing. If you believe that you have a personal interest in this proposal and you wish to inform the Company of such personal interest, you should submit such information in advance of voting to the Company at its registered offices at XTL Biopharmaceuticals Ltd., 85 Medinat ha-Yehudim St., Herzliya, Israel, to the attention of Mr. Noam Band, Chief Executive Officer.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” approval of the proposed resolution.

 

PROPOSAL 6:

APPOINTMENT OF AUDITOR

 

Background

 

On June 29, 2026, our shareholders approved the appointment of BARZILY & Co. C.P.A. (the “Auditors”) as the Company’s independent registered public accounting firm for the year ending December 31, 2025, in place of KPMG. Our Audit Committee and Board of Directors have approved, subject to shareholder approval, the re-appointment of the Auditors for the year ending December 31, 2026, and recommend that the Board of Directors, upon the recommendation of the Audit Committee, be authorized to determine the Auditors’ remuneration in accordance with the volume and nature of their services to the Company.

 

Proposed Resolution

 

It is proposed that at the Meeting the following resolution be adopted:

 

“RESOLVED, to approve the re-appointment of BARZILY & CO. C.P.A as the Company’s independent registered public accounting firm for the year ending December 31, 2026, and to authorize the Board of Directors, upon the recommendation of the Company’s audit committee, to determine the Auditors’ remuneration to be fixed in accordance with the volume and nature of their services to the Company for such fiscal year.”

 

Required Vote

 

The affirmative vote of the holders of a majority of the voting power represented and voting on this proposal in person or by proxy is necessary for the approval of the resolution to approve the appointment of the Company’s independent auditor.

 

Board Recommendation

 

The Board of Directors recommends a vote “FOR” approval of the proposed resolution.

 

Page 13

 

 

OTHER BUSINESS

 

Other than as set forth above, as of the mailing of this Proxy Statement, management knows of no business to be transacted at the extraordinary meeting, but, if any other matters are properly presented at the extraordinary meeting, the persons named in the attached form of proxy will vote upon such matters in accordance with their best judgment.

 

  By Order of the Board of Directors
   
  /s/ Noam Band
  Noam Band
  Chief Executive Officer
  Dated: November 20, 2026

 

Page 14

 

Exhibit 99.2

 

XTL Biopharmaceuticals Ltd.

 

PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

TO BE HELD ON DECEMBER 28, 2026 

 

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS.

 

The undersigned hereby appoints Noam Band, Chief Executive Officer, attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to vote on behalf of the undersigned all the ordinary shares in XTL Biopharmaceuticals Ltd. (the “Company”) which the undersigned is entitled to vote at the Extraordinary General Meeting of Shareholders (the “Extraordinary Meeting”) to be held at the offices of the Company’s attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel on Monday, December 28, 2026 at 4:00 p.m. (Israel time), and at any adjournments or postponements thereof, upon the following matters, which are more fully described in the Notice of an Extraordinary General Meeting of Shareholders (the “Notice”) and Proxy Statement relating to the Extraordinary Meeting (“Proxy Statement”).

 

The undersigned acknowledges receipt of the Notice of the Extraordinary General Meeting of Shareholders and Proxy Statement of the Company relating to the Meeting. All terms that are not defined in this Proxy shall have the same meaning of such terms in the Notice and/or the Proxy Statement.

 

This Proxy, when properly executed, will be voted in the manner directed herein by the undersigned. If no direction is made with respect to any matter, this Proxy will be voted FOR such matter. Any and all proxies heretofore given by the undersigned are hereby revoked.

 

 

(Continued and to be signed on the reverse side)

 

 

 

 

 

EXTRAODINARY GENERAL MEETING OF SHREHOLDERS OF

XTL BIOPHARMACEUTICALS LTD.

 

December 28, 2026, 4:00 p.m. (Israel time)

 

Please date, sign and mail

your proxy card in the

envelope provided as soon

as possible.

 

THE BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” EACH OF THE PROPOSALS FOR THE MEETING

 

PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.

PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE ☒

 

1.To elect Mr. Guy Rosen to serve as an external director of the Company, in place of Ms. Iris Shapira Yalon, for an initial term of three (3) years commencing on the date of the Meeting, and to approve his compensation terms, all as more fully described in the Proxy Statement.

 

  ☐ for ☐ against ☐ abstain

 

2.Subject to the approval of Proposal 1, to approve the grant of options to purchase 1,000,000 ordinary shares of the Company to Mr. Guy Rosen.

 

  ☐ for ☐ against ☐ abstain

 

3.To approve the change of the Company’s name from “XTL Biopharmaceuticals Ltd.” to “Psyga Ltd.” (in Hebrew: “פסייגה בע"מ”), or such other similar name as shall be approved by the Israeli Registrar of Companies, and to amend the Company’s amended and restated articles of association (the “Articles of Association”) accordingly.

 

  ☐ for ☐ against ☐ abstain

 

4.To approve the engagement terms of Mr. Yaron Kopel as Chief Executive Officer of the Company, including the grant of options to purchase up to 550,000 American Depositary Shares of the Company (“ADSs”), each ADS representing 400 ordinary shares of the Company.

 

  ☐ for ☐ against ☐ abstain

 

  5. To approve, including for the purpose of Nasdaq Rule 5635(c) and 5635(d), a private placement of up to US$1,000,000 from certain investors, including Mr. Alexander Rabinovich, a director of the Company (the “Interested Party”), and the issuance of all ordinary shares (including in the form of ADSs) issuable in connection therewith or as a result thereof, including upon exercise of any warrants issued or repriced as a result of the Private Placement, as described in the Proxy Statement.

 

  ☐ for ☐ against ☐ abstain

 

6.To approve the re-appointment of Barzily & Co. C.P.A. as the Company’s independent registered public accounting firm for the year ending December 31, 2026, and to authorize the Board of Directors, upon the recommendation of the Audit Committee, to determine the auditors’ remuneration in accordance with the volume and nature of their services.

 

  ☐ for ☐ against ☐ abstain

 

 

 

 

PLEASE NOTE that by signing and submitting this proxy card, you declare that you have no personal interest in Proposals 1, 2, 4 and 5, at this Extraordinary General Meeting of the Shareholders, except for a personal interest of which you have notified the Company about in writing, as required under the Israeli Companies Law, 5759-1999. For further information, please see the accompanying proxy statement.

 

In their discretion, the proxies are authorized to vote upon such other matters as may properly come before the Extraordinary Meeting or any adjournment or postponement thereof.

 

      Date: ________, 2026       Date_________, 2026
SIGNATURE   SIGNATURE  

 

Please sign exactly as your name appears on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, trustee or guardian, please give full title as such. If the signed is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.

 

 

 

Filing Exhibits & Attachments

2 documents

Keep reading